Roidipedia.Compound reference & reporting
06 AUG 2026
CompoundsPharmaceutical Alprostadil
PharmaceuticalPharmaceuticalVasodilatorProstaglandinIntracavernosal

Alprostadil

Also known as Caverject · Edex · MUSE · Prostaglandin E1 · PGE1

Alprostadil is synthetic prostaglandin E1 used for erectile dysfunction as an intracavernosal injection (Caverject) or intraurethral pellet (MUSE). Unlike oral PDE5 inhibitors it acts locally to relax cavernosal smooth muscle independent of nerve signalling, so it works even when PDE5 inhibitors fail — but at the cost of an invasive route and a real risk of prolonged erection.

01 Overview

Alprostadil is prostaglandin E1, which raises intracellular cyclic AMP in cavernosal smooth muscle, producing relaxation and erection independent of nitric-oxide signalling. Because it bypasses the neural/NO pathway, it is effective in men who do not respond to oral PDE5 inhibitors, including some with nerve damage after prostatectomy. It is delivered directly — injected into the corpus cavernosum or inserted as a urethral pellet.

The trade-off is the invasive administration and a genuine risk of priapism (a prolonged, painful erection lasting over four hours) which is a urological emergency, as well as penile pain and, with repeated injections, fibrosis. It is a legitimate prescription therapy rather than a lifestyle drug, and self-administration requires proper training and a plan for priapism.

02 Mechanism

Synthetic prostaglandin E1: raises cAMP in cavernosal smooth muscle, producing NO-independent vasodilation and erection.

03 Dosing

TierDoseRouteNotes
Intracavernosal injection2.5–20 mcgIMInjected into the corpus cavernosum; titrated under supervision. (Route is intracavernosal, closest enum INTRAMUSCULAR.)
Intraurethral pellet125–1000 mcgRectalMUSE urethral suppository; higher doses reflect lower local bioavailability. (Route is intraurethral, closest enum RECTAL.)

04 Effects

EffectMagnitudeEvidence
Erection independent of PDE5 pathwayProduces erection even in men who fail oral PDE5 inhibitors, including post-prostatectomy nerve damage.~70% responseClinical

05 Side effects

EffectSeverityFrequencyEvidenceCountermeasures
Penile painPain at the injection site or in the penis is frequent, especially with the urethral pellet.ModerateCommonClinical
Penile fibrosis / Peyronie-like changesFibrous nodules or curvature can develop with long-term repeated injection.ModerateUncommon with repeated useClinical
Priapism (prolonged erection)An erection lasting over 4 hours is a urological emergency that can cause permanent tissue damage.SevereUncommon but urgentClinical

07 References

Intracavernosal alprostadil for the treatment of erectile dysfunctionN Engl J Med, 1996
Caverject (alprostadil) FDA labelUS FDA

08 Discussion0 comments

?
Sign in to add a comment…
Create account
Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.
This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.